No Data
No Data
Organon, Henlius Announce Phase 3 Study of HLX11 Met Primary Endpoint
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta (Pertuzumab) Biosimilar Candidate HLX11
Trending Industry Today: WUXI BIO Leads Gains In Biotechnology Stocks
Henlius Biotech's HLX11 Meets Phase 3 Trial Goals
Henlius (02696.HK): The international multicenter Phase 3 clinical study of HLX11 (recombinant anti-HER2 domain II humanized monoclonal antibody injection) for neoadjuvant treatment of HER2-positive and HR-negative early or locally advanced breast cancer
Grunt 27 Sept | henlius (02696.HK) announced that the international multicenter Phase 3 clinical study of the company's self-developed biosimilar HLX11 (recombinant anti-HER2 domain II humanized monoclonal antibody injection) for the neoadjuvant treatment of early or locally advanced HER2-positive and HR-negative breast cancer has achieved its primary endpoint. This study is a multicenter, randomized, double-blind, parallel-controlled Phase 3 clinical trial designed to compare HLX11 with the original Perjeta as an overall treatment.
Express News | Shanghai Henlius Biotech - International Multi-Center Phase 3 Clinical Study of Hlx11 Met Primary Study Endpoint
No Data
No Data